RXRX

Recursion Pharmaceuticals, Inc.

12.83 USD
-0.63 (-4.68%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Recursion Pharmaceuticals, Inc. stock is up 36.34% since 30 days ago. The next earnings date is May 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 6 PUTs, 4 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
29 Feb 14:40 15 Mar, 2024 19.00 PUT 80 80
29 Feb 14:40 19 Apr, 2024 20.00 PUT 50 70
29 Feb 14:51 21 Jun, 2024 12.00 PUT 1033 39
29 Feb 15:36 19 Apr, 2024 12.00 CALL 100 164
29 Feb 15:41 16 Jan, 2026 15.00 CALL 100 1202
29 Feb 16:17 15 Mar, 2024 11.00 CALL 100 1539
29 Feb 16:18 20 Sep, 2024 14.00 CALL 100 156
29 Feb 18:45 19 Apr, 2024 12.00 PUT 305 472
01 Mar 15:20 21 Jun, 2024 12.00 PUT 1174 1216
01 Mar 15:20 21 Jun, 2024 13.00 PUT 1174 1623

About Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation. REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer.